643 related articles for article (PubMed ID: 21932937)
1. Role of everolimus in pancreatic neuroendocrine tumors.
Goldstein R; Meyer T
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1653-65. PubMed ID: 21932937
[TBL] [Abstract][Full Text] [Related]
2. Everolimus: a new treatment option for advanced pancreatic neuroendocrine tumors.
Thompson LA; Kim M; Wenger SD; O'Bryant CL
Ann Pharmacother; 2012 Sep; 46(9):1212-9. PubMed ID: 22947595
[TBL] [Abstract][Full Text] [Related]
3. Everolimus in the treatment of renal cell carcinoma and neuroendocrine tumors.
Chan HY; Grossman AB; Bukowski RM
Adv Ther; 2010 Aug; 27(8):495-511. PubMed ID: 20623346
[TBL] [Abstract][Full Text] [Related]
4. Everolimus 10 mg and pancreatic neuroendocrine tumours: many adverse effects and uncertain benefit.
Prescrire Int; 2012 Oct; 21(131):234. PubMed ID: 23185844
[TBL] [Abstract][Full Text] [Related]
5. Medical treatment of neuroendocrine tumours.
Weber HC
Curr Opin Endocrinol Diabetes Obes; 2013 Feb; 20(1):27-31. PubMed ID: 23221494
[TBL] [Abstract][Full Text] [Related]
6. Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.
Bollard J; Couderc C; Blanc M; Poncet G; Lepinasse F; Hervieu V; Gouysse G; Ferraro-Peyret C; Benslama N; Walter T; Scoazec JY; Roche C
Neuroendocrinology; 2013; 97(4):331-40. PubMed ID: 23343749
[TBL] [Abstract][Full Text] [Related]
7. Everolimus for the treatment of pancreatic neuroendocrine tumors.
Feldmann G; Bisht S; Schütte U; Haarmann J; Brossart P
Expert Opin Pharmacother; 2012 Oct; 13(14):2073-84. PubMed ID: 22873789
[TBL] [Abstract][Full Text] [Related]
8. [Management of metabolic disorders induced by everolimus in patients with differentiated neuroendocrine tumors: expert proposals].
Lombard-Bohas C; Cariou B; Vergès B; Coriat R; N'guyen T; François E; Hammel P; Niccoli P; Hentic O
Bull Cancer; 2014 Feb; 101(2):175-83. PubMed ID: 24557872
[TBL] [Abstract][Full Text] [Related]
9. Long-term everolimus treatment of patients with pancreatic neuroendocrine tumors.
Wolin EM
Chemotherapy; 2014; 60(3):143-50. PubMed ID: 25766415
[TBL] [Abstract][Full Text] [Related]
10. Everolimus for advanced pancreatic neuroendocrine tumors.
Yao JC; Shah MH; Ito T; Bohas CL; Wolin EM; Van Cutsem E; Hobday TJ; Okusaka T; Capdevila J; de Vries EG; Tomassetti P; Pavel ME; Hoosen S; Haas T; Lincy J; Lebwohl D; Öberg K;
N Engl J Med; 2011 Feb; 364(6):514-23. PubMed ID: 21306238
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine tumors of the digestive tract: impact of new classifications and new agents on therapeutic approaches.
Oberg K
Curr Opin Oncol; 2012 Jul; 24(4):433-40. PubMed ID: 22510940
[TBL] [Abstract][Full Text] [Related]
12. Safety and efficacy of everolimus in gastrointestinal and pancreatic neuroendocrine tumors after (177)Lu-octreotate.
Kamp K; Gumz B; Feelders RA; Kwekkeboom DJ; Kaltsas G; Costa FP; de Herder WW
Endocr Relat Cancer; 2013 Dec; 20(6):825-31. PubMed ID: 24036133
[TBL] [Abstract][Full Text] [Related]
13. Recent studies show promise for treating rare pancreatic tumors.
Peres J
J Natl Cancer Inst; 2011 Apr; 103(8):624-7. PubMed ID: 21474831
[No Abstract] [Full Text] [Related]
14. Advances in the treatment of pancreatic neuroendocrine tumours.
Gao F; Visvardis EE; Sita-Lumsden A; Waxman J
QJM; 2012 Sep; 105(9):819-22. PubMed ID: 22383691
[TBL] [Abstract][Full Text] [Related]
15. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
[TBL] [Abstract][Full Text] [Related]
16. Rationale and protocol of the MetNET-1 trial, a prospective, single center, phase II study to evaluate the activity and safety of everolimus in combination with octreotide LAR and metformin in patients with advanced pancreatic neuroendocrine tumors.
Pusceddu S; de Braud F; Concas L; Bregant C; Leuzzi L; Formisano B; Buzzoni R
Tumori; 2014; 100(6):e286-9. PubMed ID: 25688512
[TBL] [Abstract][Full Text] [Related]
17. [Neuroendocrine tumors: the age of targeted therapies].
Capdevila J; Argilés G; Mulet-Margalef N; Tabernero J
Endocrinol Nutr; 2012; 59(7):438-51. PubMed ID: 22565119
[TBL] [Abstract][Full Text] [Related]
18. Pancreatic neuroendocrine tumors: entering a new era.
Oberstein PE; Remotti H; Saif MW; Libutti SK
JOP; 2012 Mar; 13(2):169-73. PubMed ID: 22406593
[TBL] [Abstract][Full Text] [Related]
19. Pancreatic neuroendocrine tumors: signal pathways and targeted therapies.
Peng L; Schwarz RE
Curr Mol Med; 2013 Mar; 13(3):333-9. PubMed ID: 23331005
[TBL] [Abstract][Full Text] [Related]
20. From targets to treatments: a review of molecular targets in pancreatic neuroendocrine tumors.
Wiedenmann B; Pavel M; Kos-Kudla B
Neuroendocrinology; 2011; 94(3):177-90. PubMed ID: 21893937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]